Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 8, 2006

View Archived Issues

rhIL-11 induces sTNFRI shedding, alleviates chemotherapy-induced mucositis

Novel approach to cancer immunotherapy with genetically engineered lymphocytes

Ghrelin analogue shows efficacy for CHF-associated cardiac cachexia

A2A receptor antagonists come forth as potential cancer immunotherapeutics

High-dose rNAPc2 improves ischemia in patients with NSTE-ACS

Salix licenses U.S. rights to Sanvar IR

Enrollment completed in phase II/III study of MN-001 in interstitial cystitis

NicOx provides full update on status of lead programs and collaborations

Clolar studied in older patients with AML

Xanthus licenses targeted cancer compounds from Schering

LX-6171 for cognitive disorders begins phase I study

Phase II trial studies CDA-1 and MDX-1388 in C. difficile associated diarrhea

GSK reports on a novel candidate for histamine H3 antagonism in AD

Phase II study evaluates R-788 for rheumatoid arthritis

Israeli approval for phase II study of CF-101 in keratoconjunctivitis sicca

Abuse resistant drug ELI-216 studied in phase II

Astellas profiles new promising agent to enhance bisphosphonate therapy in osteoporosis

AlphaVax reports phase I findings for HIV vaccine

Anthera licenses antiinflammatory compounds from Lilly and Shionogi

Dynavax and AstraZeneca collaborate on TLR-9 agonists for asthma and COPD

Laquinimod reduces rate of inflammatory disease activity in MS patients

Novel therapeutic strategies for metabolic disorders described in recent patents

Novel therapeutic agents for asthma described in recent patents

Scripps patent discloses novel transthyretin amyloid inhibitors for amyloidosis

Abbott seeks approval for Humira in Crohn's disease in U.S. and E.U.

Plavix approved in Europe for patients with STEMI

Sanofi-aventis withdraws dronedarone MAA with plans to resubmit

Takeda discontinues development of TAK-654 for diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....